• Je něco špatně v tomto záznamu ?

BOK displays cell death-independent tumor suppressor activity in non-small-cell lung carcinoma

E. Moravcikova, E. Krepela, VS. Donnenberg, AD. Donnenberg, K. Benkova, T. Rabachini, Y. Fernandez-Marrero, D. Bachmann, T. Kaufmann,

. 2017 ; 141 (10) : 2050-2061. [pub] 20170807

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S.

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016469

As the genomic region containing the Bcl-2-related ovarian killer (BOK) locus is frequently deleted in certain human cancers, BOK is hypothesized to have a tumor suppressor function. In the present study, we analyzed primary non-small-cell lung carcinoma (NSCLC) tumors and matched lung tissues from 102 surgically treated patients. We show that BOK protein levels are significantly downregulated in NSCLC tumors as compared to lung tissues (p < 0.001). In particular, we found BOK downregulation in NSCLC tumors of grades two (p = 0.004, n = 35) and three (p = 0.031, n = 39) as well as in tumors with metastases to hilar (pN1) (p = 0.047, n = 31) and mediastinal/subcarinal lymph nodes (pN2) (p = 0.021, n = 18) as opposed to grade one tumors (p = 0.688, n = 7) and tumors without lymph node metastases (p = 0.112, n = 51). Importantly, in lymph node-positive patients, BOK expression greater than the median value was associated with longer survival (p = 0.002, Mantel test). Using in vitro approaches, we provide evidence that BOK overexpression is inefficient in inducing apoptosis but that it inhibits TGFβ-induced migration and epithelial-to-mesenchymal transition (EMT) in lung adenocarcinoma-derived A549 cells. We have identified epigenetic mechanisms, in particular BOK promoter methylation, as an important means to silence BOK expression in NSCLC cells. Taken together, our data point toward a novel mechanism by which BOK acts as a tumor suppressor in NSCLC by inhibiting EMT. Consequently, the restoration of BOK levels in low-BOK-expressing tumors might favor the overall survival of NSCLC patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016469
003      
CZ-PrNML
005      
20180516110413.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.30906 $2 doi
035    __
$a (PubMed)28744854
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Moravcikova, Erika $u Institute of Pharmacology, Faculty of Medicine, University of Bern, Bern, Switzerland. Department of Cardiothoracic Surgery, School of Medicine, University of Pittsburgh, PA.
245    10
$a BOK displays cell death-independent tumor suppressor activity in non-small-cell lung carcinoma / $c E. Moravcikova, E. Krepela, VS. Donnenberg, AD. Donnenberg, K. Benkova, T. Rabachini, Y. Fernandez-Marrero, D. Bachmann, T. Kaufmann,
520    9_
$a As the genomic region containing the Bcl-2-related ovarian killer (BOK) locus is frequently deleted in certain human cancers, BOK is hypothesized to have a tumor suppressor function. In the present study, we analyzed primary non-small-cell lung carcinoma (NSCLC) tumors and matched lung tissues from 102 surgically treated patients. We show that BOK protein levels are significantly downregulated in NSCLC tumors as compared to lung tissues (p < 0.001). In particular, we found BOK downregulation in NSCLC tumors of grades two (p = 0.004, n = 35) and three (p = 0.031, n = 39) as well as in tumors with metastases to hilar (pN1) (p = 0.047, n = 31) and mediastinal/subcarinal lymph nodes (pN2) (p = 0.021, n = 18) as opposed to grade one tumors (p = 0.688, n = 7) and tumors without lymph node metastases (p = 0.112, n = 51). Importantly, in lymph node-positive patients, BOK expression greater than the median value was associated with longer survival (p = 0.002, Mantel test). Using in vitro approaches, we provide evidence that BOK overexpression is inefficient in inducing apoptosis but that it inhibits TGFβ-induced migration and epithelial-to-mesenchymal transition (EMT) in lung adenocarcinoma-derived A549 cells. We have identified epigenetic mechanisms, in particular BOK promoter methylation, as an important means to silence BOK expression in NSCLC cells. Taken together, our data point toward a novel mechanism by which BOK acts as a tumor suppressor in NSCLC by inhibiting EMT. Consequently, the restoration of BOK levels in low-BOK-expressing tumors might favor the overall survival of NSCLC patients.
650    _2
$a adenokarcinom $x genetika $x metabolismus $x sekundární $7 D000230
650    12
$a apoptóza $7 D017209
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a nemalobuněčný karcinom plic $x genetika $x metabolismus $x sekundární $7 D002289
650    _2
$a spinocelulární karcinom $x genetika $x metabolismus $x sekundární $7 D002294
650    _2
$a epitelo-mezenchymální tranzice $7 D058750
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x genetika $x metabolismus $x patologie $7 D008175
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny c-bcl-2 $x genetika $x metabolismus $7 D019253
650    _2
$a míra přežití $7 D015996
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
700    1_
$a Krepela, Evzen $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Donnenberg, Vera S $u Department of Cardiothoracic Surgery, School of Medicine, University of Pittsburgh, PA.
700    1_
$a Donnenberg, Albert D $u Department of Medicine, School of Medicine, University of Pittsburgh, PA.
700    1_
$a Benkova, Kamila $u Department of Pathology, Hospital Bulovka, Prague, Czech Republic.
700    1_
$a Rabachini, Tatiana $u Institute of Pharmacology, Faculty of Medicine, University of Bern, Bern, Switzerland.
700    1_
$a Fernandez-Marrero, Yuniel $u Institute of Pharmacology, Faculty of Medicine, University of Bern, Bern, Switzerland.
700    1_
$a Bachmann, Daniel $u Institute of Pharmacology, Faculty of Medicine, University of Bern, Bern, Switzerland.
700    1_
$a Kaufmann, Thomas $u Institute of Pharmacology, Faculty of Medicine, University of Bern, Bern, Switzerland.
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 141, č. 10 (2017), s. 2050-2061
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28744854 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180516110548 $b ABA008
999    __
$a ok $b bmc $g 1300093 $s 1013309
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 141 $c 10 $d 2050-2061 $e 20170807 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace